Empowered Funds LLC cut its position in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 43.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,555 shares of the company's stock after selling 21,941 shares during the period. Empowered Funds LLC's holdings in HCA Healthcare were worth $9,867,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in HCA Healthcare by 11.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,454 shares of the company's stock valued at $8,796,000 after purchasing an additional 2,698 shares in the last quarter. Brown Advisory Inc. lifted its holdings in HCA Healthcare by 53.9% during the first quarter. Brown Advisory Inc. now owns 4,630 shares of the company's stock worth $1,600,000 after buying an additional 1,622 shares during the period. Farther Finance Advisors LLC lifted its holdings in HCA Healthcare by 26.9% during the first quarter. Farther Finance Advisors LLC now owns 1,141 shares of the company's stock worth $395,000 after buying an additional 242 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in HCA Healthcare by 2.5% during the first quarter. Oppenheimer Asset Management Inc. now owns 4,314 shares of the company's stock worth $1,491,000 after buying an additional 105 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in HCA Healthcare by 17.6% during the first quarter. GAMMA Investing LLC now owns 4,931 shares of the company's stock worth $1,704,000 after buying an additional 737 shares during the period. 62.73% of the stock is owned by institutional investors.
HCA Healthcare Stock Performance
Shares of NYSE HCA traded up $2.69 during trading on Friday, reaching $405.54. 761,184 shares of the company traded hands, compared to its average volume of 1,129,364. The firm's fifty day simple moving average is $382.88 and its 200 day simple moving average is $362.77. The stock has a market cap of $94.89 billion, a P/E ratio of 17.05, a PEG ratio of 1.27 and a beta of 1.41. HCA Healthcare, Inc. has a 12-month low of $289.98 and a 12-month high of $420.98. The company has a current ratio of 0.98, a quick ratio of 0.86 and a debt-to-equity ratio of 69.07.
HCA Healthcare (NYSE:HCA - Get Free Report) last released its quarterly earnings data on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, beating analysts' consensus estimates of $6.20 by $0.64. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.The business had revenue of $18.61 billion during the quarter, compared to analyst estimates of $18.49 billion. During the same quarter last year, the business posted $5.50 EPS. The company's revenue was up 6.4% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. As a group, research analysts anticipate that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.
HCA Healthcare Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Tuesday, September 16th will be given a dividend of $0.72 per share. The ex-dividend date is Tuesday, September 16th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.7%. HCA Healthcare's dividend payout ratio (DPR) is 12.11%.
Insider Transactions at HCA Healthcare
In related news, EVP Michael S. Cuffe sold 3,836 shares of HCA Healthcare stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the sale, the executive vice president directly owned 31,503 shares in the company, valued at approximately $13,194,716.52. The trade was a 10.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.30% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the company. Wells Fargo & Company lowered their target price on HCA Healthcare from $385.00 to $375.00 and set an "equal weight" rating for the company in a report on Thursday, August 14th. Bank of America upped their price target on HCA Healthcare from $375.00 to $410.00 and gave the stock a "neutral" rating in a research report on Wednesday. Wall Street Zen raised HCA Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $444.00 price target on shares of HCA Healthcare in a research report on Tuesday, August 26th. Finally, Truist Financial upped their target price on HCA Healthcare from $390.00 to $415.00 and gave the company a "buy" rating in a research report on Wednesday, July 16th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $403.17.
Check Out Our Latest Stock Report on HCA
HCA Healthcare Profile
(
Free Report)
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Further Reading

Before you consider HCA Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HCA Healthcare wasn't on the list.
While HCA Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.